[
    [
        {
            "time": "",
            "original_text": "揭秘送转股183只除权以来股价上涨",
            "features": {
                "keywords": [
                    "送转股",
                    "除权",
                    "股价上涨"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "股票市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "揭秘送转股183只除权以来股价上涨",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【国元医药|点评】安科生物2021年中报预告点评：业绩表现超预期，生长激素维持高速增长态势",
            "features": {
                "keywords": [
                    "安科生物",
                    "中报",
                    "业绩超预期",
                    "生长激素",
                    "高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药|点评】安科生物2021年中报预告点评：业绩表现超预期，生长激素维持高速增长态势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "泉源堂成本承压三年累亏4亿 DTP药房资本梦如何圆？",
            "features": {
                "keywords": [
                    "泉源堂",
                    "成本压力",
                    "亏损",
                    "DTP药房",
                    "资本化"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药零售"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泉源堂成本承压三年累亏4亿 DTP药房资本梦如何圆？",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]